Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Regulatory / Erasca class action lawsuit
Regulatory class action

Erasca class action lawsuit

Analysis based on 17 articles · First reported Jun 28, 2026 · Last updated Jul 16, 2026

Sentiment
-60
Attention
2
Articles
17
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Erasca's stock price plummeted nearly 59% over two days following the patent infringement allegations and adverse clinical data. The class action lawsuit adds further legal and financial uncertainty, potentially impacting investor confidence and the company's ability to raise capital.

biotechnology pharmaceuticals
Event Summary

A class action lawsuit has been filed against Erasca (Nasdaq: ERAS) by Pomerantz LLP, alleging securities fraud or other unlawful business practices. The lawsuit follows a series of disclosures on April 27, 2026, when Erasca revealed it received a letter from Revolution Medicines, Inc. alleging patent infringement and trade secret misappropriation related to Erasca's drug candidate ERAS-0015. Additionally, Erasca reported preliminary Phase 1 clinical data for ERAS-0015, including a patient death. These disclosures caused Erasca's stock price to drop significantly, falling 10.71% on April 27 and an additional 48.3% on April 28, 2026. Investors have until August 10, 2026, to seek lead plaintiff status.

Key Actions
93 Erasca reported preliminary clinical data
90 Revolution Medicines sent letter alleging infringement Erasca
85 Rosen Law Firm announced class action lawsuit Erasca
80 Faruqi & Faruqi filed class action Erasca
80 The Law Offices of Frank R. Cruz filed securities fraud class action Erasca
75 Glancy Prongay & Murray filed class action lawsuit Erasca
73 Pomerantz LLP filed class action lawsuit Erasca
72 The Schall Law Firm reminded investors of lawsuit Erasca
Entities Involved
stock
Erasca
Erasca is the defendant in a securities class action lawsuit and faces patent infringement allegations from Revolution Medicines. Its stock price dropped sharply after disclosing a patient death in a clinical trial and a patent dispute.
Importance 100.0 Sentiment -80.0
stock
Revolution Medicines
Revolution Medicines is the plaintiff in a patent infringement and trade secret misappropriation claim against Erasca. The allegations contributed to Erasca's stock decline, potentially benefiting Revolution Medicines competitively.
Importance 60.0 Sentiment 30.0
priv
Pomerantz LLP
Pomerantz LLP is the law firm that filed the class action lawsuit against Erasca on behalf of investors. The firm is seeking lead plaintiff status for investors who purchased Erasca securities during the class period.
Importance 40.0 Sentiment 0.0
exch
Nasdaq
Erasca is listed on Nasdaq under the ticker ERAS. The exchange is not directly impacted by the event but is the venue where Erasca's stock trades.
Importance 10.0 Sentiment 0.0
Relationships
Erasca competitor ↔ Revolution Medicines Erasca is a clinical-stage oncology company that directly competes with Revolution Medicines in developing pan-RAS molec
Pomerantz LLP related ↔ Nasdaq
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.